http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2015227544-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74b7b50944d8e1960440fb1f5440b7fd |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
filingDate | 2015-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f0197f190929943d8a119692ab51cfc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70204eac846a7f0c7a310cf16dedb3f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_265f1cf209e24dfc1e550faa6233bc9b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf05de8c9d2b6edbe6a1522479b044fb |
publicationDate | 2015-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2015227544-A1 |
titleOfInvention | Methods and compositions for treating complement-associated disorders |
abstract | Abstract The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b. |
priorityDate | 2008-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 677.